Liquid Biopsy Market

Liquid Biopsy Industry worth $11.3 billion by 2029, with a CAGR of 11.9%

The report "Liquid Biopsy Market by Product & Service (Kits, Instruments), Circulating Biomarker (CTC, ctDNA, cfDNA), Technology (NGS, PCR), Application (Cancer (Lung, Breast, Prostate), Non-cancer (NIPT, Infectious)), Sample Type (Blood) - Global Forecast to 2029", is valued at an estimated USD 6.4 billion in 2024 and is projected to reach USD 11.3 billion by 2029 at a CAGR of 11.9% during the forecast period.

Browse 406 market data Tables and 56 Figures spread through 343 Pages and in-depth TOC on "Liquid Biopsy Market by Product & Service (Kits, Instruments), Circulating Biomarker (CTC, ctDNA, cfDNA), Technology (NGS, PCR), Application (Cancer (Lung, Breast, Prostate), Non-cancer (NIPT, Infectious)), Sample Type (Blood) - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/liquid-biopsy-market-13966350.html

In recent years, there has been substantial growth in the liquid biopsy market. The increasing burden of cancer cases globally has highlighted the urgent requirement for more effective and less invasive diagnostic tools. In this context, liquid biopsy emerges as a highly valuable solution. Unlike traditional tissue biopsies, which often involve invasive procedures and can be associated with discomfort and risks for patients, liquid biopsy offers a non-invasive alternative for detecting and monitoring cancer. Furthermore, these tests can also be used in non-invasive prenatal testing and transplantation medicine. Thus, these advantages are driving the rapid evolution and uptake of liquid biopsy products and services in disease diagnosis, treatment, and monitoring.

In 2023, the assay kits segment held the largest share of the liquid biopsy market by product & service segment.

Based on product & service, the liquid biopsy market has been segmented into assay kits, instruments, and services. The assay kits segment dominated the liquid biopsy market in 2023. The versatility of assay kits contributes to their market dominance. These kits are adaptable to various biomarkers and analytes, accommodating the diverse needs of liquid biopsy applications, from detecting circulating tumor DNA (ctDNA) to monitoring treatment response and disease progression. 

The therapy selection segment held the largest share of the liquid biopsy market by clinical application segment in 2023.

Based on clinical applications, the liquid biopsy market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring.  In 2023, the largest share of the liquid biopsy market was held by the therapy selection segment. The growth of therapy selection as the major clinical application segment is fueled by the advantages of liquid biopsy over traditional methods with its minimally invasive, real-time monitoring capabilities across various cancer types, its integration into clinical trials and drug development processes, and its cost-effectiveness in guiding therapy selection.

North America is the largest regional market for liquid biopsy market.

The market for liquid biopsy has been divided into six key geographical regions, namely North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. In 2023, North America held the predominant portion of the liquid biopsy market. The region boasts a well-developed healthcare infrastructure, including advanced diagnostic facilities, specialized oncology centers, and a skilled workforce. This infrastructure supports the integration of liquid biopsy into routine clinical practice, facilitating access for patients across various healthcare settings.

The major players operating in this market are Natera, Inc. (US), QIAGEN (Netherlands), Myriad Genetics, Inc. (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (US), uardant Health (US), Bio-Rad Laboratories, Inc. (US), Exact Sciences Corporation (US), Sysmex Corporation (Japan), Biocept, In. (US), mdxhealth (US), Personalis, Inc. (US), NeoGenomics Laboratories (US), Epigenomics AG (Germany), ANGLE plc (UK), Menarini-Silicon Biosystems (Italy), Vortex Biosciences (US), Bio-Techne (US), MedGenome (US), Mesa Labs, Inc. (US), Laboratory Corporation of America Holdings (US), Freenome Holdings, Inc. (US), Strand (India), LungLife AI, Inc. (US), and Lucence Health Inc. (US).

Don’t miss out on business opportunities in Liquid Biopsy Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

Liquid Biopsy Market Size,  Share & Growth Report
Report Code
MD 4456
PR Published ON
5/8/2024
Choose License Type
BUY NOW
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Liquid Biopsy Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status
...

Digital Virtual Assistant - MarketsandMarkets

Home